Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANAB NASDAQ:ARVN NASDAQ:CLLS NASDAQ:SVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$22.00+4.3%$23.14$12.21▼$40.70$616.42M-0.19739,590 shs125,786 shsARVNArvinas$8.17+7.4%$7.49$5.90▼$29.61$601.31M2.382.11 million shs538,887 shsCLLSCellectis$2.63$2.34$1.10▼$3.24$146.18M3.03216,747 shs42,132 shsSVRASavara$3.72+3.8%$2.68$1.89▼$4.70$647.29M0.561.28 million shs1.31 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio-6.39%+4.77%-10.98%-11.01%-43.20%ARVNArvinas-3.67%-1.93%0.00%+1.06%-69.72%CLLSCellectis+1.54%+1.15%+3.95%+86.52%+14.35%SVRASavara+4.68%+9.48%+32.59%+46.72%-18.82%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$22.00+4.3%$23.14$12.21▼$40.70$616.42M-0.19739,590 shs125,786 shsARVNArvinas$8.17+7.4%$7.49$5.90▼$29.61$601.31M2.382.11 million shs538,887 shsCLLSCellectis$2.63$2.34$1.10▼$3.24$146.18M3.03216,747 shs42,132 shsSVRASavara$3.72+3.8%$2.68$1.89▼$4.70$647.29M0.561.28 million shs1.31 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio-6.39%+4.77%-10.98%-11.01%-43.20%ARVNArvinas-3.67%-1.93%0.00%+1.06%-69.72%CLLSCellectis+1.54%+1.15%+3.95%+86.52%+14.35%SVRASavara+4.68%+9.48%+32.59%+46.72%-18.82%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANABAnaptysBio 2.80Moderate Buy$46.13109.66% UpsideARVNArvinas 2.55Moderate Buy$19.76141.90% UpsideCLLSCellectis 3.00Buy$4.0052.09% UpsideSVRASavara 2.83Moderate Buy$6.6779.45% UpsideCurrent Analyst Ratings BreakdownLatest CLLS, ANAB, ARVN, and SVRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025SVRASavaraHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $8.008/15/2025SVRASavaraOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$5.00 ➝ $6.008/15/2025SVRASavaraHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$2.00 ➝ $5.008/12/2025ANABAnaptysBioUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$18.00 ➝ $20.008/7/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$40.00 ➝ $45.008/7/2025ARVNArvinasHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$24.00 ➝ $18.008/7/2025ARVNArvinasWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$19.00 ➝ $16.008/7/2025ARVNArvinasGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$16.00 ➝ $15.007/24/2025ANABAnaptysBioJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$42.00 ➝ $80.00(Data available from 9/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANABAnaptysBio$91.28M6.75N/AN/A$2.33 per share9.44ARVNArvinas$263.40M2.28N/AN/A$8.17 per share1.00CLLSCellectis$49.22M2.97N/AN/A$2.36 per share1.11SVRASavaraN/AN/AN/AN/A$1.00 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANABAnaptysBio-$145.23M-$4.48N/AN/AN/A-107.66%-366.98%-30.58%11/4/2025 (Estimated)ARVNArvinas-$198.90M-$1.01N/AN/AN/A-19.47%-12.01%-6.97%10/29/2025 (Estimated)CLLSCellectis-$36.76M-$0.82N/AN/AN/A-100.69%-68.05%-21.53%11/3/2025 (Estimated)SVRASavara-$95.88M-$0.50N/AN/AN/AN/A-69.05%-54.84%11/11/2025 (Estimated)Latest CLLS, ANAB, ARVN, and SVRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q1 2025SVRASavara-$0.12-$0.14-$0.02-$0.14N/AN/A8/6/2025Q2 2025ANABAnaptysBio-$1.50-$1.34+$0.16-$1.34$11.55 million$22.26 million8/6/2025Q2 2025ARVNArvinas-$0.87-$0.84+$0.03-$0.84$34.42 million$22.40 million8/4/2025Q2 2025CLLSCellectis-$0.15-$0.24-$0.09-$0.24$10.07 million$18.19 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANABAnaptysBioN/AN/AN/AN/AN/AARVNArvinasN/AN/AN/AN/AN/ACLLSCellectisN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANABAnaptysBioN/A8.228.22ARVNArvinasN/A5.645.64CLLSCellectis0.581.381.38SVRASavara0.2511.0811.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANABAnaptysBioN/AARVNArvinas95.19%CLLSCellectis63.90%SVRASavara87.93%Insider OwnershipCompanyInsider OwnershipANABAnaptysBio33.50%ARVNArvinas4.73%CLLSCellectis16.41%SVRASavara5.33%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANABAnaptysBio10028.00 million18.62 millionOptionableARVNArvinas42073.42 million69.95 millionOptionableCLLSCellectis29055.58 million46.46 millionOptionableSVRASavara20172.84 million163.63 millionOptionableCLLS, ANAB, ARVN, and SVRA HeadlinesRecent News About These CompaniesHC Wainwright Issues Positive Forecast for Savara (NASDAQ:SVRA) Stock Price3 hours ago | marketbeat.comSavara Inc. $SVRA Shares Bought by Bain Capital Life Sciences Investors LLCSeptember 5 at 7:56 AM | marketbeat.comSavara (NASDAQ:SVRA) Given New $8.00 Price Target at HC WainwrightSeptember 5 at 4:03 AM | americanbankingnews.comSavara (NASDAQ:SVRA) Stock Price Up 4.8% Following Analyst UpgradeSeptember 5 at 2:16 AM | americanbankingnews.comADAR1 Capital Management LLC Raises Stock Position in Savara Inc. $SVRASeptember 4 at 7:41 AM | marketbeat.comVestal Point Capital LP Purchases 225,000 Shares of Savara Inc. $SVRASeptember 4 at 7:17 AM | marketbeat.comFrazier Life Sciences Management L.P. Acquires 2,801,922 Shares of Savara Inc. $SVRASeptember 4 at 6:50 AM | marketbeat.comSavara price target raised to $8 from $5 at H.C. WainwrightSeptember 3 at 4:06 PM | msn.comNantahala Capital Management LLC Has $22.37 Million Stock Holdings in Savara Inc. $SVRASeptember 3 at 7:05 AM | marketbeat.com207,299 Shares in Savara Inc. $SVRA Bought by Walleye Capital LLCSeptember 3 at 4:19 AM | marketbeat.comNuveen LLC Acquires New Stake in Savara Inc. $SVRASeptember 3 at 3:38 AM | marketbeat.comSavara Announces New U.S. Health Claims Data Analysis Finds Over 50% Increase in the Estimated Number of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Patients ...September 2 at 1:53 PM | joplinglobe.comJSavara Highlights MOLBREEVI Development in New PresentationSeptember 2 at 9:31 AM | tipranks.comVanguard Group Inc. Sells 190,723 Shares of Savara Inc. $SVRAAugust 31, 2025 | marketbeat.comWellington Management Group LLP Trims Stock Position in Savara Inc. $SVRAAugust 30, 2025 | marketbeat.comSavara Announces Participation in Upcoming Investor Healthcare ConferencesAugust 26, 2025 | businesswire.comSavara Inc. (SVRA) Upgraded to Buy After FDA CMC BreakthroughAugust 24, 2025 | finance.yahoo.comSavara to Present Key Research on Rare Lung Disease at ERS Congress 2025August 24, 2025 | msn.comSavara Inc. (SVRA) Upgraded to Buy After FDA CMC BreakthroughAugust 23, 2025 | insidermonkey.comNew England Journal of Medicine (NEJM) to Publish Results From Savara’s Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)August 22, 2025 | finance.yahoo.com3 Best Stocks to Buy Now, 8/22/2025, According to Top AnalystsAugust 22, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLLS, ANAB, ARVN, and SVRA Company DescriptionsAnaptysBio NASDAQ:ANAB$22.00 +0.91 (+4.31%) As of 01:19 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Arvinas NASDAQ:ARVN$8.17 +0.56 (+7.36%) As of 01:20 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Cellectis NASDAQ:CLLS$2.63 0.00 (0.00%) As of 01:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Savara NASDAQ:SVRA$3.72 +0.14 (+3.77%) As of 01:19 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Affirm Crushes Earnings Expectations, Turns Bears into Believers Gold’s Explosive Rally: GDX ETF May Be the Fast Track to Profits Microsoft’s AI Push Beyond OpenAI Could Drive Next Breakout Dollar Tree Plunges Into Buy-Zone: A Robust Rebound Is Expected Zscaler Shares Can Hit a Fresh High Before Year-End Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
